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ABSTRACT
Dysregulation of transforming growth factor-β1 (TGF-β1) and insulin-like growth
factor (IGF) axis has been linked to reactive stroma dynamics in prostate cancer
progression. IGF binding protein-3 (IGFBP3) induction is initiated by stroma remodeling
and could represent a potential therapeutic target for prostate cancer. In previous
studies a lead quinazoline-based Doxazosin® derivative, DZ-50, impaired prostate tumor
growth by targeting proteins involved in focal adhesion, anoikis resistance and epithelialmesenchymal-transition (EMT). This study demonstrates that DZ-50 increased expression
of the epithelial marker E-cadherin, and decreased the mesenchymal marker N-cadherin
in human prostate cancer cells. In DU-145 cells, the effect of DZ-50 on EMT towards
mesenchymal epithelial transition (MET) was inhibited by talin1 overexpression, a focal
adhesion regulator promoting anoikis resistance and tumor invasion. DZ-50 treatment
of human prostate cancer cells and cancer-associated fibroblasts (CAFs) downregulated
IGFBP3 expression at mRNA and protein level. In TGF-β1 responsive LNCaPTβRII, TGF-β1
reversed DZ-50-induced MET by antagonizing the drug-induced decrease of nuclear
IGFBP3. Furthermore, co-culture with CAFs promoted prostate cancer epithelial cell
invasion, an effect that was significantly inhibited by DZ-50. Our findings demonstrate that
the lead compound, DZ-50, inhibited the invasive properties of prostate cancer epithelial
cells by targeting IGFBP3 and mediating EMT conversion to MET. This study integrated
the mechanisms underlying the effect of DZ-50 and further supported the therapeutic
value of this compound in the treatment of advanced metastatic prostate cancer.

[3, 4]. However, after ADT the majority of patients
eventually develop castration-resistant prostate cancer
(CRPC) [4, 5]. The recognition that CRPC is driven by
aberrant androgen signaling and androgen receptor (AR),
led to the utilization of AR-directed second generation
antiandrogens, abiraterone and enzalutamide for the
treatment of metastatic CRPC (mCRPC) [5, 6]. Taxanes,
including docetaxel and cabazitaxel, are 1st and 2nd line
chemotherapy respectively, for the treatment of patients
with mCRPC developing resistance to ADT [7], and
contribute to only a modest improvement of survival
[8–10]. Overriding this resistance requires understanding

INTRODUCTION
Prostate cancer accounts for 21% of cancer
diagnoses and 8% of cancer-related deaths in men
with a total of 180,890 new cases and 26,120 deaths
estimated in 2016 in the United States [1]. Advances in
diagnostic, surgical and radiotherapy approaches have
been shown to have a significant impact on impairing
tumor progression and improve patient survival [2].
Androgen deprivation therapy (ADT) including medical
or surgical castration remains the primary treatment
option for prostate cancer patients with metastatic disease
www.impactjournals.com/oncotarget
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of the driving mechanisms, besides the AR in CRPC in the
context of the tumor microenvironment and development
of targeted therapeutics.
The heterogeneity characterizing the prostate
gland consists of luminal epithelial cells, basal cells
and a small number of neuroendocrine cells among the
epithelium in the surrounding stroma [11]. The reactive
prostate stroma within the microenvironment functionally
contributes to prostate cancer initiation, progression
and metastasis [12]; with stroma-derived transcriptome
signatures shown to be of strong predictive value of patient
survival, disease progression and therapeutic resistance
[12]. Normal fibroblasts maintain tissue homeostasis,
however, myofibroblasts and cancer-associated fibroblasts
(CAFs) facilitate tumor progression via their repair-centric
system and pro-survival biology, promoting tumor growth
and vascularity [13]. Taking control of the dynamics of
prostate stroma microenvironment is the multifunctional
cytokine transforming growth factor-β1 (TGF-β1);
activation of TGF-β1 signaling mediates the transition of
fibroblast to myofibroblasts [14] and promotes prostate
cancer cell-mediated differentiation of normal fibroblasts
into CAFs towards metastasis [13, 15].
Additional growth factor signaling networks
contextual to the tumor microenvironment are functionally
involved in prostate tumor growth and progression
including the insulin growth-factor (IGF) signaling
axis [16, 17]. IGF ligand binds to the IGF-I receptor, a
transmembrane tyrosine kinase receptor, and subsequently
IGF-II receptor to activate downstream signaling cascades,
such as AKT, promoting cell proliferation and survival
[16]. Stimulation of the IGF-I axis up-regulates zinc
finger E-box-binding protein1 (ZEB1) which promotes
the process of epithelial-mesenchymal-transition (EMT) in
human prostate cancer cells [18]. EMT is characterized by
loss of epithelial protein E-cadherin and upregulation of
mesenchymal proteins (N-cadherin and vimentin); ZEB1
facilitates EMT by acting as a transcriptional repressor
of E-cadherin expression [18], towards invasion and
metastasis. A clinically significant increase in serum and
prostatic tissue levels of IGF ligands has been detected
in prostate cancer patients [16]. IGFs also bind to IGFbinding proteins (IGFBPs), with IGFBP3 being the most
abundant carrier of IGF ligands in serum [16, 17]. IGFBP3
inhibits IGF signaling due to high-affinity binding to
IGFs and subsequent sequestration of the ligand or due
to IGF-independent mechanisms [16, 17]. Moreover,
IGFBP3 can promote IGF action in diverse human
cells including skin fibroblasts [19], breast carcinoma
cells [20] and prostate cancer cells overexpressing a
constitutively active AR [21]. Mechanistic dissection in
cultured fibroblasts indicated that IGFBP3 potentiates
IGF action via the phosphatidylinositol-3-kinase pathway
[22]. In human esophageal epithelial cells, IGFBP3,
in an IGF independent mechanism, promotes TGF-β1mediated EMT and activates transcriptional regulators
www.impactjournals.com/oncotarget

essential in EMT, including snail, ZEB1 and ZEB2 [23].
Specifically, IGFBP3 loss suppressed TGF-β1-mediated
EMT, while IGFBP3I56G/L80G/L81G, a mutant IGFBP3 lacking
IGF binding capacity, prevented the IGFBP3 knockdown
effect. Furthermore, IGFBP3I56G/L80G/L81G promoted EMT
in vivo in a Ras-transformed esophageal xenograft model
[23], implicating an IGF independent action of IGFBP3 to
promote EMT.
Our previous studies on the structural optimization
of the quinazoline-based α1-adrenoceptor antagonist
Doxazosin®, led to the generation of a lead derivative,
DZ-50, that impaired prostate tumor growth through
anoikis [24, 25]. A genome-wide microarray analysis and
pathway association analysis of pre-clinical models [24]
identified that DZ-50 down-regulated genes encoding
regulators of extracellular matrix (ECM), tight junctions,
angiogenesis, and a component of IGF axis involved in
prostate stroma remodeling (IGFBP3) [14]. The present
study focused on characterizing the role of IGFBP3 in
TGF-β1-mediated EMT and reversal to MET in response
to the drug. We found that DZ-50 antagonized TGFβ1-promoted cell invasion by targeting IGFBP3 in both
prostate cancer epithelial cells and CAFs, supporting its
therapeutic value.

RESULTS
Induction of MET in prostate cancer epithelial
cells by DZ-50
Cell viability of DU-145 and DU-145talin1 was
decreased by DZ-50 in a concentration dependent manner
(Figure 1A). Our previous studies demonstrated that DZ50 at 5µM downregulated talin1 expression and druginduced anoikis was prevented by talin1 overexpression
[24]. In the current study, the ability of DZ-50 to reduce
cell viability after 48hrs of treatment was compromised
by talin1 overexpression. The effect of DZ-50 on
mRNA expression of IGFBP3, E-cadherin, N-cadherin,
Vimentin, Slug/Snail (E-cadherin repressor), and ZEB1
was subsequently profiled (Figure 1B). Within 3hrs of
treatment there was a significant decrease in IGFBP3
mRNA expression, and an increase in E-cadherin mRNA.
A temporal decrease in mRNA levels for N-cadherin,
vimentin and slug was detected after 6hrs of exposure
to the drug. DZ-50-induction of E-cadherin mRNA and
downregulation of N-cadherin, slug and snail mRNA were
prevented by elevated talin1 (Figure 1B). Phenotypic EMT
profiling in DU-145 and DU-145talin1 cells revealed that
DZ-50 (2µM; 48hrs) decreased IGFBP3, N-cadherin,
ZEB1 and vimentin protein expression (Figure 1C).
The effect of DZ-50 on N-cadherin and vimentin was
antagonized by talin1 overexpression (Figure 1C).
The human prostate cancer cells LNCaP, lack TGF-β
type II receptor and thus are refractory to effect of TGF-β1;
genetically-engineered overexpression of the type II
78508
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receptor restores sensitivity of LNCaP cells to TGF-β1
[26, 27]. Treatment with DZ-50 significantly inhibited
cell viability in both the LNCaP and LNCaPTβRII cells
in a concentration- and time-dependent manner (Figure 2,
panels A and B respectively); this effect of the drug was
antagonized by TGF-β signaling in the LNCaPTβRII cells
after 48 hrs of exposure to DZ-50. Further reduction in
cell viability in these cells was observed after 96hrs of
treatment. Expression profiling of the candidate targets
revealed that DZ-50 decreased IGFBP3 mRNA expression
within 3hrs of treatment (Figure 2C) with a consequential
decrease in IGFBP3 protein levels (by 24hrs) (Figure 2D)
in the LNCaP, but not in the LNCaPTβRII cells. There
was reduced N-cadherin protein expression, paralleled
by elevated E-cadherin after 48hrs of drug exposure
(Figure 2D), indicating a reversal to epithelial phenotype
(MET). The intrinsically active TGF-β signaling in

the LNCaPTβRII prostate cancer cells antagonized
the inhibitory effect of DZ-50 on IGFBP3 expression.
Expression of ZEB1, AR and β-catenin was not affected
by the drug (Figure 2D).
We subsequently investigated the functional
consequences of IGFBP3 loss on the sensitivity of
LNCaPTβRII cells to DZ-50. As shown on Figure 2
(panels E and F), IGFBP3 knockdown led to E-cadherin
mRNA and protein upregulation and a modest N-cadherin
mRNA decrease. The effect of IGFBP3 loss on E-cadherin
mRNA was prevented by DZ-50 exposure (Figure 2G).
No significant differences were detected in mRNA
expression for Snail and ZEB1 by IGFBP3 knockdown
regardless of the presence of DZ-50 (Figure 2E and 2G).
IGFBP3 knockdown however enhanced the sensitivity
of LNCaPTβRII cells to the drug, further reducing cell
viability (Figure 2H).

Figure 1: Effect of DZ-50 on prostate cancer cell death and EMT. Panel A, indicates the response of human prostate cancer cells

to increasing concentrations of DZ-50. Cell viability was inhibited in both DU-145 and DU-145talin1 cells in a dose- and time-dependent
manner by DZ-50, n=4;*p<0.05. Panel B, reveals the mRNA expression profile of EMT regulators IGFBP3, E-cadherin (E-cad), N-cadherin
(N-cad), vimentin (Vim), Slug, Snail and ZEB1 in response to DZ-50 (2µM). mRNA levels were determined by RT-PCR; n≥6; *p<0.05.
Panel C, Effect of DZ-50 on IGFBP3, E-cadherin, N-cadherin, β-catenin, vimentin, talin1 and ZEB1 protein expression (by Western blot).
www.impactjournals.com/oncotarget
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Figure 2: Functional involvement of IGFBP3 in the reversion of EMT to MET in prostate cancer cells. Panels

A and B, reveal the dose response and time course of DZ-50 treatment of prostate cancer cells LNCaP and LNCaPTβRII. DZ-50
decreased cell viability in both cell lines; n=4; *p<0.05 compared to control. Panel C, indicates the effect of DZ-50 (4 µM) on
IGFBP3 mRNA; n = 6. *p<0.05. Panel D, Western blot analysis of ZEB1, E-cadherin, N-cadherin, AR, β-catenin, and IGFBP3
protein levels in response to DZ-50 (4 µM, 24-48hrs). Panels E and F, shows the consequences of IGFBP3 loss on EMT regulators
mRNA (by RT-PCR) and protein expression (by Western blot); n = 5. *p<0.05. Panel G, the effect of DZ-50 (3hrs; 4µM) on mRNA
expression after IGFBP3 knockdown (n=5; *p<0.05). Panel H, reveals the effect of IGFBP3 silencing on LNCaPTβRII cell response
to DZ-50 (4µM, 48hrs); n=3; *p<0.05.

www.impactjournals.com/oncotarget
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DZ-50 decreased nuclear expression of IGFBP3
in LNCaPTβRII cells

ZEB1, N-cadherin, β-catenin, or vimentin levels (Figure
4D).

LNCaP and LNCaPTβRII cells were treated with
DZ-50 (4µM) for 24hrs in the presence or absence of
TGF-β1 (5ng/ml), and subjected to confocal microscopy.
For both the LNCaP and LNCaPTβRII cells, E-cadherin
was primarily localized on cell membrane regardless of
the presence of the drug (Supplementary Figure 1A and
Figure 3A). IGFBP3 was distributed in both cytoplasmic
and nuclear fractions of the cells (Supplementary Figure 1A
and Figure 3A), with a predominant nuclear localization in
LNCaPTβRII cells (Figure 3A). DZ-50-induced membrane
localization of IGFBP3 and E-cadherin was inhibited by
TGF-β1 in these cells (Figure 3A); in LNCaP cells there was
no apparent effect by TGF-β1 (Supplementary Figure 1A).
Western blot analysis of protein in subcellular
fractions from LNCaPTβRII cells, revealed that TGF-β1
increased cytosolic IGFBP3 levels with no effect on
nuclear protein. Treatment with DZ-50 decreased IGFBP3
expression in the nuclear, while it increased IGFBP3
levels in the cytosol (Figure 3B). DZ-50 treatment in
the presence of TGF-β1, sustained elevated cytosolic
IGFBP3, but had no effect on nuclear levels. The above
change of the fractional expression of IGBFP3 resulted
in the diffused distribution of the protein by the drug
alone or in combination with TGF-β1 as shown by
confocal microscopy (Figure 3A). In LNCaP cells, DZ50 decreased nuclear IGFBP3 levels, with no apparent
effect on cytosolic protein levels regardless of TGF-β1
presence (Supplementary Figure 1B). There was no effect
on IGFBP3, AR, E- and N-cadherin in LNCaP cells by
TGF-β1 (Supplementary Figure 2). TGF-β1 led to reduced
E-cadherin and increased total IGFBP3 expression in
LNCaPTβRII cells, while it reversed DZ-50-induced
N-cadherin decrease (Figure 3C). Smad4 expression was
not affected by DZ-50 (Supplementary Figure 3).

DZ-50 inhibited DU-145 and LNCaP cell
migration in CAF co-culture
In order to recapture the stroma component of the
prostate tumor microenvironment, co-cultures of CAFs
and prostate cancer epithelial cells were used to evaluate
the effect of DZ-50 on cell migration. As shown on Figure
5 (panel A), co-culture of DU-145 and DU-145talin1
cells with prostate CAFs promoted prostate cancer cell
migration, an effect that was impaired by DZ-50 (2µM).
The CAF-mediated-cell migration in the androgensensitive cell lines LNCaPTβRII (Figure 5B), and LNCaP
(Supplementary Figure 5), was significantly inhibited by
DZ-50 treatment. In the LNCaPTβRII cells, the ability of
TGF-β1 to directly promote prostate cancer cell migration
was also blocked by DZ-50 (Figure 5B).

DISCUSSION
This study provides the first evidence on the impact of
our lead quinazoline agent, DZ-50, on EMT reversion to the
MET phenotype in different human prostate cancer cell lines
and in co-culture cell models (with CAFs), via targeting
IGFBP3. The drug-induced MET was prevented by talin1
overexpression in DU-145 androgen-independent prostate
cancer cells, in accord with recent evidence suggesting that
talin1 loss impaired EMT and consequential acquisition
of cell motility [28]. DU-145 talin1 overexpressing cells
developed resistance to DZ-50-induced anoikis [24] and
acquisition of the mesenchymal phenotype induced by
talin1 overexpression was associated with the anoikis
resistance [29]. In addition, phosphoinositide-generating
enzyme, PIPKIγ, and talin1 together control the adhesion
and phosphoinositide signaling that regulates EMT [28],
indicating that important coupling enzymes in addition to
talins are required for EMT induction. The involvement of
talin1 in cadherin regulated cell-cell attachment is supported
by evidence suggesting that a novel calpain-dependent
proteolytic cleavage of talin1 results in the release of a 70kD C-terminal fragment that rescues the cell-cell adhesion
formation [30]. One could thus easily argue that talin1
overexpression might generate more calpain-dependent
proteolytic cleaved protein, recruiting E-cadherin to the
cell membrane. Interestingly enough, in DU-145 cells,
E-cadherin was not upregulated by DZ-50, which could
be due to posttranslational modification such as protein
degradation. In that context one may consider that several
E3 ubiquitin ligases are involved in EMT regulation, and
genetic alterations of these ligases have been found in
prostate cancer [31, 32].
TGF-β1 promotes prostate tumor migration, invasion
and metastatic spread through navigating functional
interactions within the tumor microenvironment [10]. Co-

DZ-50 decreased IGFBP3 expression in CAFs
Cell viability of CAFs derived from Patient 2 and
9 (Supplementary Table 1) was decreased by DZ-50 in
a dose- dependent manner (Figure 4A; Supplementary
Figure 4C). CAFs derived from Patient 9 were more
resistant to DZ-50 treatment compared to those from
Patient 2 (Figure 4A; Supplementary Figure 4C). DZ50 (2µM) inhibited IGFBP3 mRNA expression in CAFs
derived from Patient 2 and Patient 10 (Supplementary
Table 1) after 6hrs, and 3/6hrs treatment, respectively
(Figure 4B). The drug had no effect on IGFBP3 mRNA/
protein expression in CAFs derived from Patient 9
(Supplementary Figure 4A and 4B). The highest IGFBP3
mRNA level was detected in prostate tumor with the
highest Gleason score (4+5) (Figure 4C). DZ-50 treatment
decreased IGFBP3 protein expression in CAFs (derived
from Patient 2 and 10), but had no significant effect on
www.impactjournals.com/oncotarget
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culture with CAFs promoted prostate cancer epithelial
cell migration and invasion via TGF-β1, consistent
with a TGF-β1-induced EMT phenotype, which was
pharmacologically inhibited (by DZ-50). In the TGF-β1responsive LNCaPTβRII cells, DZ-50 promoted MET by
downregulating nuclear IGFBP3, an action antagonized
by TGF-β1. Considering that IGFBP3 promotes TGFβ1-mediated EMT by activating critical transcriptional
regulators, including Snail and ZEB1 in human esophageal

epithelial cells [23], the DZ-50 targeting of nuclear IGFBP3
could be driving the drug-induced MET. The present findings
provide new insights into the ability of TGF-β1 to modify the
response of prostate cancer cells to DZ-50. Mechanistically,
TGF-β1 previously shown to upregulate IGFBP3 [23, 26],
may directly antagonize the effect of DZ-50 on IGFBP3 and
prevent pharmacologically-induced MET (schematically
shown on Figure 5C). Functional silencing of IGFBP3
in prostate cancer epithelial cells resulted in increased

Figure 3: Effect of DZ-50 on nuclear IGFBP3 in LNCaPTβRII cells. Panel A, representative confocal images of IGFBP3 and

E-cadherin localization in LNCaPTβRII cells. Cells were exposed to DZ-50 (24hrs), in the absence or presence of TGF-β1 (5ng/ml) and
subjected to fluorescent labeling for IGFBP3, E-cadherin and DAPI. Magnification, X60. Panel B, Western blot analysis of subcellular
fractions for IGFBP3 protein after treatment with DZ-50 (48hrs) in presence/absence of TGF-β1 (5ng/ml). Panel C, Western blot of
E-cadherin, N-cadherin and IGFBP3 levels after DZ-50 exposure (4µM, 48hrs) in the presence/absence of TGF-β1. The blot is representative
of three independent experiments.
www.impactjournals.com/oncotarget
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E-cadherin, while neither of the transcriptional repressors,
Snail or ZEB1 mRNA expression was significantly affected
(by IGFBP3 knockdown) begging the question as to its
role in EMT-MET cycling. An alternative pathway through
which IGFBP3 regulates EMT, might involve interaction
of nuclear IGFBP3 with the E-cadherin DNA promoter.
Such a possibility gains support from reports in other
systems indicating the interaction of IGFBP3 with nuclear
receptors (retinoid receptors, PPARγ and Nur77), as well
as the histone-DNA complex [33]. Import of IGFBP3 into
the nucleus is mediated by binding to importin-β (i.e.,
Karyopherin-β) to form the importin-α/β nuclear transport
complex, sharing a common pathway with IGFBP5 [34–36].
The focus on nuclear localization of IGFBP3 takes particular
significance as the nuclear protein (IGFBP3) has been
previously associated with human prostate cancer recurrence
[37]. TGF-β1 prevented the effect of DZ-50 on nuclear
IGFBP3 and EMT reversal, supporting the involvement

of nuclear IGFBP3 in promoting EMT [10], in accord
with evidence that IGFBP3 enhanced TGF-β1-mediated
fibroblast differentiation towards EMT [14]. Here we propose
a new effect of DZ-50 on nuclear IGFBP3 mediating the
pharmacologic reversion of EMT to MET in prostate cancer
cells (Figure 5C). The impact of DZ-50 treatment on this
nuclear transport dynamic is currently being investigated in
pre-clinical models of prostate cancer progression.
In esophageal squamous cell carcinoma, IGFBP3
promotes tumor progression in a subset of tumor cells with
a concurrent high expression of CD44 [38]. CD44, a major
cell surface hyaluronic acid receptor, is involved in invasion,
metastasis and drug resistance in many human malignancies
including prostate cancer [38, 39]. High CD44 expression
is a characteristic of cancer stem cells functionally linked
to prostate cancer metastasis [40]. Switch from CD44+ cell
to EMT cell is regulated by TGF-β1-CD44 signaling as a
critical step in prostate cancer cell metastasis [41]. Thus

Figure 4: CAFs Response to DZ-50. Panel A, shows the effect of DZ-50 on cell viability in CAFs derived from Patient 2. DZ-50

decreased cell viability in CAFs in a dose- and time-dependent manner, n=4; *p<0.05. Panel B, expression profile of IGFBP3 mRNA in
CAFs derived from Patient 2 and 10 in response to DZ-50, n≥6; *p<0.05. Panel C, IGFBP3 mRNA expression in prostate tumors. Panel
D, shows the expression profile for IGFBP3, N-cadherin, β-catenin, vimentin and ZEB1 proteins in patient-derived CAFs after DZ-50
treatment (2µM, 24-48hrs).
www.impactjournals.com/oncotarget
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one can speculate on a potential engagement of IGFBP3 by
the TGF-β1-CD44 signaling of EMT in prostate tumors. In

addition, the functional contribution of IGFBP3 to prostate
cancer cell apoptosis [42], involves the IGFBP3-mediated

Figure 5: Effect of DZ-50 on CAF-mediated migration of prostate cancer cells. Panel A, shows fluorescent images of migrated

DU-145 and DU-145talin1 cells co-cultured with CAFs in the absence/presence of DZ-50 (2µM; 24hrs) and respective numerical data from
quantitative analysis. Panel B, shows fluorescent images of migrated LNCaPTβRII cells co-cultured with CAFs in the absence/presence of
the drug (2µM; 24hrs), TGF-β1 (5ng/ml; 24 hrs), and TGF-β1NA (TGF-β1 neutralizing antibody; 500ng/ml); numerical data were analyzed
as described in “Materials and Methods”; Magnification x40; *p<0.05. Panel C, schematic illustration of pathway via which DZ-50 dictates
EMT to MET conversion and CAF-facilitated prostate cancer cell migration via targeting nuclear localization of IGFBP3.
www.impactjournals.com/oncotarget
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MATERIALS AND METHODS

translocation of Nur77 from the nucleus to mitochondria
[43]. Moreover while IGFBP3 enhanced doxorubicininduced apoptosis, it also promoted survival under serum
starvation, indicating a dual role for IGFBP3 in human
endothelial cells [44]. At the molecular level, IGFBP3
activated SphK1 and led to S1P-dependent transactivation
of EGFR in normal mammary epithelial and breast cancer
cells [45, 46]. SphK1 activation by IGFBP3 has been
implicated in resistance to chemotherapy-induced DNA
damage by forming nuclear complexes with EGFR and
DNA-PKcs [47]. The IGF axis is involved in prostate cell
proliferation, differentiation and apoptosis [48, 49]. Clinical
evidence has established a positive correlation between
elevated IGF-1Rs in prostate stroma tissue and Gleason
grade, and down-regulation of epithelial IGFBP3 in prostate
cancer patients [50]. Positioning a role for IGFBP3 in the
tumor microenvironment, elevated IGFBP3 in stroma
tissue was found in pre-clinical models of prostate cancer
resonating with the evidence in human prostate cancer
specimens [23, 51].
Prostate stroma heterogeneity in prostate cancer
could account for the differential response of CAFs
(from different patients) to DZ-50. CAFs derived from
high grade prostate tumor harboring the highest IGFBP3
mRNA levels, exhibited resistance to the drug, compared
to CAFs from low-grade tumors. The differences in the
response of CAFs from patient 2 vs patient 9 to DZ-50, as
well as the differential IGFBP3 mRNA expression among
the six prostate tumors (from individual patients), could
be driven by the stroma and tumor heterogeneity that
characterizes prostate tumors and the microenvironment
[52, 53]. Thus heterogeneity in tumor stroma constitution
and its functional interaction with tumor epithelial
cells may “calibrate” therapeutic sensitivity. A better
understanding of functional interactions between
fibroblasts and tumor epithelial cells, as mediated by
IGFBP3, will define the role of stroma to therapeutic
resistance in advanced prostate cancer [53].
Our findings taken together with clinical evidence
that IGFBP3 promoter polymorphism contributes to
prostate cancer risk [54, 55], and its potential biomarker
value in prostate cancer patients [56], support the
clinical significance of IGFBP3. This study enhances
our understanding of a new dynamic in the prostate
tumor stroma involving IGFBP3 as an EMT regulator,
and its impact on the therapeutic response of cancer
epithelial cells. The effect of the new agent, DZ-50, on
MET induction and TGF-β1-mediated prostate tumor
cell migration by targeting IGFBP3, may facilitate a new
therapeutic optimization platform for the treatment of
advanced CRPC.

www.impactjournals.com/oncotarget

Cell cultures and drugs
Human prostate cancer cell lines PC-3, DU-145,
LNCaP were obtained from the American Type Tissue
Culture Collection (Rockville, MD). Primary prostatic
CAFs are provided by Dr. S. Koochekpour (Roswell
Park Cancer Institute, Buffalo, NY). The LNCaP cells
overexpressing the TGF-β receptor II (LNCaPTβRII) [26],
DU-145 cells overexpressing talin1 (DU-145 talin1) [57],
and prostate cancer cells co-cultured with primary prostatic
CAFs [58] have been established in our laboratory. DZ-50,
a first-generation doxazosin quinazoline derivative was
used as the novel therapeutic agent [25].

Antibodies
Antibodies against specific proteins were obtained
as follows: The monoclonal antibody against N-cadherin
from Abcam (San Francisco, CA); for E-cadherin from
BD Biosciences (San Jose, CA); antibodies against
the human β-catenin and vimentin from Cell Signaling
Technology (Beverly, MA); monoclonal antibodies against
ZEB1 and IGFBP3 were from the Bethyl Laboratories
(Montgomery, TX) and Santa Cruz Biotechnology (Dallas,
TX) respectively; the antibody against talin1 was obtained
from EMD Millipore (Billerica, MA).

Western blot analysis
Cell lysates from prostate cells were subjected to
Western blotting as previously described [58]. Subcellular
fractionation was performed using NE-PER nuclearcytoplasmic fraction kit (Thermo Scientific, Rockford,
IL). Protein samples were analyzed by SDS-PAGE
and transferred to Hybond-C membranes (Amersham
Pharmacia Biotech, Inc; Piscataway, NJ). Membranes
were incubated with the respective primary antibody
(4°C), and exposed to species-specific peroxidase-labeled
secondary antibodies. Signal detection was achieved and
visualized using a UVP Imaging System. Protein bands
were normalized to GAPDH expression.

Cell viability assay
Cell viability was evaluated using the Thiazolyl Blue
Tetrazolium bromide (MTT, Thermo Fisher Scientific,
Waltham, MA) assay as previously described [8]. Briefly
cells were seeded into 24-well plates and after grown to
60% to 75% confluence, were treated with vehicle or DZ50 at indicated doses (DMSO, Sigma-Aldrich, St. Louis,
MO). Absorbance was measured at 570nm and 690nm
using μQuant Spectrophotometer (Biotech Instruments
Inc., Winooski, VT).
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Quantitative RT-PCR analysis

Cell migration assay

RNA was extracted with the TRIzol reagent (Life
Technologies, Waltham, MA), and RNA samples (1μg)
were subjected to reverse transcription using the Reverse
Transcription System (Promega, Madison, WI) [8].
TaqMan real-time RT-PCR (Life Technologies, Waltham,
MA) analysis of the cDNA samples was conducted in an
ABI7700 Sequence Detection System (Life Technologies,
Waltham, MA) using the specific primers: E-cadherin
(CDH1; Hs01023894_m1), N-cadherin (CDH2; Hs00983056_m1), Snail (SNAI1; Hs00195591_m1), Slug (SNAI2;
Hs00161904_m1), Zeb1 (ZEB1; Hs00232783_m1),
vimentin (VIM; Hs00185584_m1), IGFBP3 (IGFBP3;
Hs00365742_g1), and 18S rRNA (4319413E; Applied
Biosystems, Life Technologies, Waltham, MA). Data
represent average values from three independent experiments;
numerical data normalized to 18s rRNA.

CellTracker Green CMFDA dye (5 μmol/L;
Invitrogen, Waltham, MA) dissolved in DMSO were
added to flask culturing CAF (45mins, 37°C) as previously
described [58]. CellTracker Orange CMTML (Invitrogen,
Waltham, MA) in 1640 RPMI was added to prostate cancer
cells, DU-145, DU-145talin1 and LNCaPTβRII, (45 mins,
37°C). Labeled cell suspensions of CAFs were placed
into the 24-well plate included in the Biocat Matrigel
Transwell Chamber (Corning, Bedford, MA). Labeled
prostate cancer epithelial cells were seeded respectively
in the transwell inserts placed (in 24-well plates) in the
absence or presence of DZ-50, and/or TGF-β1 ligand (5
ng/mL, R&D System, Minneapolis, MN), and TGF-β1
neutralizing antibody (NA; R&D System, Minneapolis,
MN). Invading prostate cancer cells were visualized
using an epifluorescence Nikon Eclipse E600 microscope
(Nikon, Melville, New York).

RNA silencing

Statistical analysis

The siRNA knocking down IGFBP3 was obtained
from Dharmacon (Lafayette, CO) with negative
control sequence included. LNCaPTβRII cells were
transfected either with a human IGFBP3 SMAT pool
siRNA (GCUACAAAGUUGACUACGA; GAAAUGCUAGUGAGUCGGA; GCACAGAUACCCAGAACUU;
GAAUAUGGUCCCUGCCGUA; 50 ng/ml) or with
an NC pool siRNA (UGGUUUACAUGUCGACUAA;
UGGUUUACAUGUUGUGUGA; UGGUUUACAUGUUUUCUGA; UGGUUUACAUGUUUUCCUA; 50 ng/ml;)
in a solution containing DharmaFECT 3 Transfection
Reagent (1µl/ml in antibiotic-free RPMI medium), at 37°C
for 48hrs. IGFBP3 silencing at the mRNA and protein
level was assessed by RT-PCR and Western blot analysis
respectively. Transfected cells were treated with DZ-50
(4µM) for 3hrs and RT-PCR assays were performed as
above.

The Student t-test, one-way, or two-way ANOVA
were performed using GraphPad Prism 6 software to
determine the statistical significance of difference between
means/treatments. All numerical data are presented as
mean± SEM. Statistical significance was set at p < 0.05.

Abbreviations
ADT, androgen deprivation therapy; CAFs, cancerassociated fibroblasts; CRPC, castration-resistant prostate
cancer; EMT, epithelial-mesenchymal transition; TGF-β1,
transforming growth factor-β1; IGF, insulin-like growth
factor; IGFBP3, insulin growth factor binding protein-3;
LNCaPTβRII, LNCaP cells overexpressing TGF-β
receptor II; MET, mesenchymal-epithelial transition;
ZEB1, E-box-binding protein1.

Immunofluorescent confocal microscopy
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plates as previously described [8]. Cells were exposed to
medium (RPMI1640 with 10% FBS) in the presence of
DZ-50 (4 µM), TGF-β1 (5ng/ml), or in combination of
the two agents. Following treatment, cells were fixed in
4% paraformaldehyde and permeabilized with 0.1% Triton
X-100 in sterile PBS. Fixed cells were incubated overnight
with primary antibody specific for IGFBP3 and E-cadherin
(Santa Cruz Biotechnology, Dallas, TX; BD Biosciences,
San Jose, CA) at 4°C and the appropriate Alexa-Fluor
(Life Technologies, Waltham, MA) fluorescent secondary
antibody (1hr, room temperature). Slides were mounted
using Vectashield mounting medium with DAPI (Vector
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Center Core, University of Kentucky, Lexington, KY).
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